PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24 th Annual Meeting of the Society of Urologic ...
The MarketWatch News Department was not involved in the creation of this content. -- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with papillary tumors ...
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (n=13) Findings ...
Transaction provides Ferring with significant non-dilutive capital to support the manufacturing capacity expansion, commercialization and further clinical development of Adstiladrin for bladder cancer ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring's intravesical gene therapy Adstiladrin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results